Serum malondialdehyde in different stages of chronic renal disorder

Background: Chronic kidney disease (CKD) is a widespread public health problem, which may have several adverse consequences such as renal failure, cardiovascular disease, and premature death. Kidney-related pathologies have increasing prevalence rates, produce a considerable financial burden, and are characterized by elevated levels of oxidative stress (OS). Several markers emerged as well-suited indicators of OS such as malondialdehyde (MDA) and lipid hydroperoxides. The reduced activities of antioxidant enzymes status and increased production of MDA in the CKD patients confirm the presence of OS. The alteration in antioxidant status and MDA in CKD patients supports the role of OS in CKD patient. Aims and Objectives: The aim of the study was to compare serum MDA in different stages of CKD with that of control. It is well known that inflammation has an important role in CKD and MDA is an oxidant biomarker. Materials and Methods: This was a cross-sectional study having 400 participants with 300 known cases of CKD and 100 healthy controls. Serum MDA levels were measured by thiobarbituric acid assay. Results: There was a significant difference between the groups regarding the MDA values (P<0.001) with that of control. The mean MDA value in Stage III (5.64±1.93 Umol/L), Stage IV (6.14±1.584 Umol/L), and Stage V (10.761±3.347 U moL/L) of CKD patients were high in comparison to healthy control (1.88±0.181 U mol/L). Conclusion: We concluded that MDA is a useful biomarker in CKD patients. The correlations of serum MDA among different stages of CKD patients were significant. Larger studies focused on CKD severity and antioxidant/oxidant biomarkers are required.